91 related articles for article (PubMed ID: 14560536)
1. Molecular markers in cervical cytology.
Altiok S
Clin Lab Med; 2003 Sep; 23(3):709-28, vii. PubMed ID: 14560536
[TBL] [Abstract][Full Text] [Related]
2. Medicolegal affairs. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
Frable WJ; Austin RM; Greening SE; Collins RJ; Hillman RL; Kobler TP; Koss LG; Mitchell H; Perey R; Rosenthal DL; Sidoti MS; Somrak TM
Acta Cytol; 1998; 42(1):76-119; discussion 120-32. PubMed ID: 9479326
[TBL] [Abstract][Full Text] [Related]
3. Atypical squamous cells: update on current concepts.
Nayar R; Tabbara SO
Clin Lab Med; 2003 Sep; 23(3):605-32. PubMed ID: 14560531
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
[TBL] [Abstract][Full Text] [Related]
5. Computerized training and proficiency testing. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
Vooijs GP; Davey DD; Somrak TM; Goodell RM; Grohs DH; Knesel EA; Mango LJ; Mui KK; Nielsen ML; Wilbur DC
Acta Cytol; 1998; 42(1):141-7. PubMed ID: 9479333
[TBL] [Abstract][Full Text] [Related]
6. The centrality of the clinician in the evaluation of patients with abnormal cervical cytologic studies.
Noller KL; Bibace R
Am J Obstet Gynecol; 2002 Dec; 187(6):1533-5. PubMed ID: 12501058
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of cervical neoplasia.
Martin CM; Astbury K; O'Leary JJ
Expert Rev Mol Diagn; 2006 Mar; 6(2):217-29. PubMed ID: 16512781
[TBL] [Abstract][Full Text] [Related]
8. Cervical adenocarcinoma identification by testing for chromosomal abnormalities.
Dittus JL; Dudley BS; Upender M; Endress GA
Arch Pathol Lab Med; 2013 Dec; 137(12):1829-31. PubMed ID: 24283864
[TBL] [Abstract][Full Text] [Related]
9. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation.
Guillaud M; Benedet JL; Cantor SB; Staerkel G; Follen M; MacAulay C
Cancer; 2006 Jul; 107(2):309-18. PubMed ID: 16773634
[TBL] [Abstract][Full Text] [Related]
10. [Epigenetic alterations in cervical cancer progression].
Ríos-Romero M; Soto-Valladares AG; Piña-Sánchez P
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S212-7. PubMed ID: 26462519
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
Wang HY; Kim H; Park KH
Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
[TBL] [Abstract][Full Text] [Related]
12. Emerging technology in cervical cancer screening: status of molecular markers.
Padilla-Paz LA
Clin Obstet Gynecol; 2005 Mar; 48(1):218-25. PubMed ID: 15725874
[No Abstract] [Full Text] [Related]
13. Cell preparation methods and criteria for sample adequacy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
McGoogan E; Colgan TJ; Ramzy I; Cochand-Priollet B; Davey DD; Grohs HK; Gurley AM; Husain OA; Hutchinson ML; Knesel EA; Linder J; Mango LJ; Mitchell H; Peebles A; Reith A; Robinowitz M; Sauer T; Shida S; Solomon D; Topalidis T; Wilbur DC; Yamauchi K
Acta Cytol; 1998; 42(1):25-32. PubMed ID: 9479321
[TBL] [Abstract][Full Text] [Related]
14. Training in cervical cytology, past, present and future.
Denton KJ
Cytopathology; 1999 Jun; 10(3):147-52. PubMed ID: 10390062
[No Abstract] [Full Text] [Related]
15. New technologies in gynecologic cytology.
Bishop JW; Marshall CJ; Bentz JS
J Reprod Med; 2000 Sep; 45(9):701-19. PubMed ID: 11027079
[TBL] [Abstract][Full Text] [Related]
16. BRCAPAP: feasibility of clinical BRCA testing on liquid-based cervical cytology: implications for biomarker development.
Muller CY; Schorge JO; Tomlinson GE; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1534-7. PubMed ID: 15342457
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
18. Cytology training in the European community: European Community Training Programme in Cervical Cancer Screening.
Coleman DV
Recent Results Cancer Res; 1993; 133():137-40. PubMed ID: 8296061
[No Abstract] [Full Text] [Related]
19. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy.
Martin CM; Astbury K; McEvoy L; O'Toole S; Sheils O; O'Leary JJ
Methods Mol Biol; 2009; 511():333-59. PubMed ID: 19347305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
